Authors

McKesson ideaShare 2026: Project Oasis Expansion and New Diabetic Retinopathy Screening Program Explained

Niki Shah, MHSA, MBA, CCHW, discusses how Project Oasis, a new diabetic retinopathy screening pilot, and the company's Community Health Worker scholarship program are working together to reduce barriers to care in under-resourced communities

Examining an Important Orphan Disease: Neurotrophic Keratitis/Keratopathy and Its Treatment

NK is a degenerative corneal disease resulting from diminished corneal innervation.

A Hospital’s Outpatient Pharmacies Attempt to Reduce DIR Fees Using Performance Reports

This quality improvement initiative demonstrates that pharmacies were unable to use performance reports provided by the payer to improve performance scores and decrease direct and indirect remuneration (DIR) fees.

DPYD Testing Gains Ground: NCCN Guideline Update Reflects Decades of Work Toward Safer Chemotherapy

The Phase 3 AMPLIFY Trial Assesses a New Treatment Paradigm in Patients With Treatment-Naive CLL

Investigators assessed fixed-duration venetoclax plus acalabrutinib with or without obinutuzumab vs chemoimmunotherapy.

Outcomes of Older Patients on Enfortumab Vedotin for Urothelial Carcinoma

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Unlocking PROTACs’ Potential: Overcoming Development Challenges

Proteolysis-targeting chimeras hold enormous potential, but also present significant challenges to drug developers.

Rebalancing Reproductive Responsibility: Progress in Nonhormonal Male Contraception

Male contraceptives represent a step toward equality in reproductive responsibility.

Evaluating the Impact of Medication Therapy Management Services Within a Health System Specialty Pharmacy

Pharmacist-led MTM services can deliver measurable clinical and financial value while advancing patient-centered care.

Evaluating Iron Sucrose Discordance: A Retrospective Health System Review

After transitioning iron sucrose 200 mg from an infusion to intravenous push, the incidence of discordance and infusion reactions were not statistically different.

Paradoxical Hypotension After Inadvertent Intravenous Administration of Epinephrine

Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.

Omalizumab: An All-in-One Allergy Wonder Drug?

Omalizumab expands its role in allergy management, now FDA-approved for food allergies, showcasing potential for broader applications in allergic rhinitis.

Just Culture Meets AI: How Pharmacists Are Leading Safer Transitions of Care

Enhancing PrEP Utilization Among Transgender Women: A Crucial Role for Pharmacists

Pharmacists can bridge gaps through education, inclusive care, and streamlined access.

Impact of Time to First Epinephrine Administration on Outcomes After In-Hospital Cardiac Arrest With Initial Nonshockable Rhythm

This study found no significant difference in the sustained return of spontaneous circulation or survival to hospital discharge based on the timing of the first epinephrine administration in these patients.

McKesson ideaShare 2025: Pharmacy of the Year Finalist Keri Bates Reflects on Teamwork, Community, and the Road Ahead

Keri Bates, PharmD, shares how the nomination validates years of hard work, highlights the deep relationships built with the community, and inspires continued growth and innovation.

Point of Pure Return: Denileukin Diftitox-cxdl for Cutaneous T-Cell Lymphoma

This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

Improving Inpatient REMS Documentation Compliance With a Wildcard Checkpoint

Using wildcard hard-stop pharmacy preparation instructions in the electronic health record system significantly improved REMs documentation compliance at our institution.

Navigating Prior Authorization Denials: A Clinical Pharmacist's Approach to Appeals

A strategic framework for pharmacists to successfully appeal prior authorization denials through evidence-based documentation, proper coding, and systematic follow-up to ensure patient medication access.

Respecting Patient Curiosity in the Age of AI: How Oncology Teams Can Respond to Unproved Cancer Therapies

Oncology teams can address AI-driven cancer cures with empathy, evidence, and safer next steps to protect patients and trust.

Bridging the Gap: Field Teams and Hubs Supporting Patient Care

Enhanced communication between field representatives and case managers improves medication access for patients with rare diseases.

Social Norm Nudging Boosts Initial Medication Adherence, Study Finds

Framing medications as common and normal improved patients' willingness to start therapy, whereas numerical adverse effect data had no significant impact.

OTC Case Studies: Self-Care for Flu

Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications

GLP-1 receptor agonists expand treatment options for diabetes, weight loss, and more, showing promise in heart failure, kidney disease, and neuroprotection.

Kratom Controversies: Exploring Use and Regulation

Understand the Inextricable Link Between the Pharmacy Revenue Cycle and 340B

By aligning the pharmacy revenue cycle with the 340B Drug Pricing Program, organizations can maximize revenue capture from medications while ensuring compliance with 340B requirements, leading to enhanced financial performance and improved care for underserved populations.

Radiation Recall in Modern Oncology: Evolving Triggers and Treatment

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Zuranolone Offers New Hope for Postpartum Depression

Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies

Here is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.

Oncology Overview: Investigational Autologous TIL Immunotherapy LN-145 for Cervical Cancer

Studies suggest novel immunotherapy may have efficacy as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.